Koers Venn Life Sciences Holdings London S.E.
Aandelen
GB00B9275X97
Biotechnologie & Medisch Onderzoek
Omzet 2023 | 56,04 mln. 70,01 mln. 65,45 mln. | Omzet 2024 * | 62,91 mln. 78,59 mln. 73,47 mln. | Marktkapitalisatie | 192 mln. 240 mln. 224 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2023 | 16 mln. 19,99 mln. 18,69 mln. | Nettowinst (verlies) 2024 * | 8 mln. 9,99 mln. 9,34 mln. | EV/omzet 2023 | 2,88 x |
Nettoliquiditeiten 2023 * | 34,79 mln. 43,46 mln. 40,63 mln. | Nettoliquiditeiten 2024 * | 43,8 mln. 54,72 mln. 51,16 mln. | EV/omzet 2024 * | 2,36 x |
K/w-verhouding 2023 |
10,1
x | K/w-verhouding 2024 * |
22,7
x | Werknemers | - |
Dividendrendement 2023 * |
1,43% | Dividendrendement 2024 * |
0,83% | Vrij verhandelbaar | 60,8% |
Recentste transcriptie over Venn Life Sciences Holdings
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Yamin Khan
CEO | Chief Executive Officer | 55 | 13-10-21 |
Ian O'Connell
FOU | Founder | 37 | 01-02-11 |
Cathal Friel
FOU | Founder | 59 | 01-02-11 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 57 | 08-06-22 | |
Cathal Friel
FOU | Founder | 59 | 01-02-11 |
Brendan Buckley
FOU | Founder | 73 | 01-12-18 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+1,51% | 42,75 mld. | |
+49,22% | 41,61 mld. | |
+8,57% | 41,34 mld. | |
-12,36% | 26,59 mld. | |
+8,92% | 25,49 mld. | |
-25,13% | 18,12 mld. | |
+29,17% | 12,24 mld. | |
-3,12% | 11,76 mld. | |
+6,35% | 11 mld. |